ArticleCancer cell international2024

ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy.

Laura Soumoy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.